Table 2.
Baseline demographic and clinical parameters among participants between mortality and survival group.
| Survival | Total death | P-value | ||
|---|---|---|---|---|
| Cardiovascular death | Non-cardiovascular death | |||
| Number | 622 | 56 | 251 | |
| Age, years | 58.91 ± 11.13 | 72.29 ± 11.55 | 71.45 ± 10.88 | <0.001 |
| Body mass index, kg/m2 | 30.18 ± 5.90 | 28.71 ± 5.95 | 29.08 ± 5.37 | 0.014 |
| Systolic blood pressure, mmHg | 127.99 ± 17.22 | 126.95 ± 21.66 | 126.63 ± 17.77 | 0.568 |
| Diastolic blood pressure, mmHg | 73.39 ± 15.68 | 64.14 ± 17.26 | 65.12 ± 16.12 | <0.001 |
| Total cholesterol, mg/dL | 206.60 ± 41.45 | 205.43 ± 54.12 | 194.22 ± 44.54 | <0.001 |
| HDL cholesterol, mg/dL | 53.16 ± 14.97 | 54.57 ± 15.38 | 51.09 ± 16.70 | 0.13 |
| C-reactive protein, mg/L | 0.67 ± 1.41 | 1.26 ± 3.59 | 0.93 ± 1.72 | 0.011 |
| Alcohol consumption, gm | 8.32 ± 22.01 | 6.51 ± 21.36 | 9.94 ± 37.37 | 0.61 |
| Selenium, μg/L | 137.08 ± 17.50 | 138.95 ± 28.73 | 135.54 ± 24.25 | 0.426 |
| eGFR, mg/min/1.73 m2 | 76.79 ± 18.21 | 60.38 ± 18.82 | 63.95 ± 22.15 | <0.001 |
| Sex, n (%) | <0.001 | |||
| Male | 300 (48.23) | 41 (73.21) | 147 (58.57) | |
| Female | 322 (51.77) | 15 (26.79) | 104 (41.43) | |
| Education level, n (%) | <0.001 | |||
| Less than high school | 180 (28.94) | 26 (46.43) | 100 (40.00) | |
| High school or above | 442 (71.06) | 30 (53.57) | 150 (60.00) | |
| Marital status, n (%) | <0.001 | |||
| Married | 209 (33.66) | 34 (60.71) | 137 (54.58) | |
| Other | 412 (66.34) | 22 (39.29) | 114 (45.42) | |
| Smoking, n (%) | 0.002 | |||
| No | 286 (45.98) | 14 (25.00) | 94 (37.45) | |
| Yes | 336 (54.02) | 42 (75.00) | 157 (62.55) | |
| Race, n (%) | <0.001 | |||
| White | 334 (53.70) | 41 (73.21) | 166 (66.14) | |
| Other races | 288 (46.30) | 15 (26.79) | 85 (33.86) | |
| Diabetes, n (%) | <0.001 | |||
| No | 478 (76.85) | 33 (58.93) | 162 (64.54) | |
| Yes | 144 (23.15) | 23 (41.07) | 89 (35.46) | |
| Cardiovascular disease, n (%) | <0.001 | |||
| No | 566 (91.44) | 39 (72.22) | 206 (83.74) | |
| Yes | 53 (8.56) | 15 (27.78) | 40 (16.26) | |
| Cancer, n (%) | <0.001 | |||
| No | 550 (88.71) | 46 (82.14) | 195 (78.31) | |
| Yes | 70 (11.29) | 10 (17.86) | 54 (21.69) | |
| Antihypertensive drugs, n (%) | <0.001 | |||
| No | 235 (37.78) | 15 (26.79) | 59 (23.51) | |
| Yes | 387 (62.22) | 41 (73.21) | 192 (76.49) | |
| Lipid-lowering drugs, n (%) | 0.07 | |||
| No | 469 (75.40) | 37 (66.07) | 173 (68.92) | |
| Yes | 153 (24.60) | 19 (33.93) | 78 (31.08) | |
| Hypoglycemic agents, n (%) | 0.004 | |||
| No | 538 (86.50) | 44 (78.57) | 195 (77.69) | |
| Yes | 84 (13.50) | 12 (21.43) | 56 (22.31) | |
| Antiplatelet drugs, n (%) | <0.001 | |||
| No | 604 (97.11) | 48 (85.71) | 241 (96.02) | |
| Yes | 18 (2.89) | 8 (14.29) | 10 (3.98) | |
N, number; HDL, high-density lipoprotein; eGFR, estimated glomerular filtration rate.
Values are mean ± standard deviation or n (%).
P-value: One-way analysis of variance (ANOVA) test for continuous data and chi-square test for categorical variables.